Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
about
Screening for prostate cancerScreening for prostate cancerCurrent status of 5alpha-reductase inhibitors in the management of lower urinary tract symptoms and BPH.Finasteride reduces the risk of incident clinical benign prostatic hyperplasiaSelenium and vitamin E for prostate cancer: post-SELECT (Selenium and Vitamin E Cancer Prevention Trial) status.Current status of 5α-reductase inhibitors in prostate disease managementFinasteride in the treatment of patients with benign prostatic hyperplasia: a reviewThe intriguing role of fibroblasts and c-Jun in the chemopreventive and therapeutic effect of finasteride on xenograft models of prostate cancer.Emerging drugs for prostate cancer.The economic burden of prostate cancer.Combination pharmacological therapies for the management of benign prostatic hyperplasia.Effect of Discontinuation of Tamsulosin in Korean Men with Benign Prostatic Hyperplasia Taking Tamsulosin and Dutasteride: An Open-Label, Prospective, Randomized Pilot Study.Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomyAre men on 5α-reductase inhibitors appropriately referred to urology? A survey of primary care physicians.The evolutionary impact of androgen levels on prostate cancer in a multi-scale mathematical model.2010 Update: Guidelines for the management of benign prostatic hyperplasia.Effect of finasteride on serum prostate-specific antigen (PSA) and on prostate of hamster Mesocricetus auratus (hMa).RETRACTED: Histopathology reports of findings of prostate needle biopsies
P2860
Q24201690-5F4EC80E-0F7D-47B3-9292-CCADB54566E1Q24245476-3DA294AF-4321-4CF9-97AB-0B23B31CEE51Q33602452-007D34CD-BA86-4227-A8CC-C1824B457B0FQ33762340-B1583EBA-D8DB-4DB6-AE01-812078D7BE2BQ34500651-2A01A1A1-5FCA-4A57-9DC6-26D9753B034EQ36778346-83DAEBB4-9CE8-4351-81F6-7841A7AFBD7CQ37261063-60F280DF-B032-4BC8-87D5-94A19B1B01D0Q37414987-68C25F49-8B4B-4B1E-9D56-C0D364D97A95Q37570555-2328B310-71FF-41A6-915F-0414FCCED683Q37925108-C6467806-18A9-42DB-AAFD-924C1A634000Q37994725-A6913800-0271-440F-85AA-7474B2F919B2Q38466939-68BF7CF0-A725-479F-993B-62F25973E588Q38922207-ACE2C761-2ECC-4CAE-A717-916AC13A7FB5Q39264461-D808A0EC-81D5-40E7-AAA8-ADAE65BF0B43Q39965082-ED4B9754-C8DB-4C19-AD38-85B3D9693587Q41054535-68B30693-E0E7-4A06-94E4-49B485BED405Q42413446-1E646705-F92C-40F0-8B65-05DFBCFC87A8Q43176592-0C84E06B-DA6D-45BC-B2CD-EFBEB45EF949Q56533035-3A70C3B5-E7BC-4D6C-B2A5-1F08A2A9F55E
P2860
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@en
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@nl
type
label
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@en
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@nl
prefLabel
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@en
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@nl
P2093
P1476
Use of 5alpha-reductase inhibi ...... 8 Clinical Practice Guideline.
@en
P2093
American Society of Clinical Oncology/American Urological Association
Barnett S Kramer
H Ballentine Carter
Jonathan I Epstein
Joseph P Costantino
Karen L Hagerty
Mark R Somerfield
Paul A Godley
Paul Schellhammer
Peter C Albertsen
P304
P356
10.1016/J.JURO.2009.01.071
P407
P50
P577
2009-02-26T00:00:00Z